Search

Your search keyword '"Augustin, Marinela"' showing total 42 results
Start Over Author "Augustin, Marinela"
42 results on '"Augustin, Marinela"'

1. The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers

Author

Roohani, Siyer, Handtke, Jolina, Hummedah, Kamal, Albertsmeier, Markus, Andreou, Dimosthenis, Apostolidis, Leonidas, Augustin, Marinela, Bauer, Sebastian, Billner, Moritz, Bösch, Florian, Deinzer, Christoph K. W., Deventer, Niklas, Duprée, Anna, Eckert, Franziska, Engel, Lars, Fechner, Katja, Fritzsche, Hagen, Gaidzik, Verena, Ghani, Saeed, Grützmann, Robert, Guder, Wiebke K., Hamacher, Rainer, Hecker, Judith S., Hendricks, Anne, Hillmann, Axel, Houben, Philipp, Hübner, Georg, Ivanyi, Philipp, Jentsch, Christina, Jordan, Maren, Kappl, Peter, Kaths, Moritz, Kessler, Torsten, Kirchberg, Johanna, Knebel, Carolin, Krempien, Robert, Lehner, Burkhard, Lenze, Ulrich, Lindner, Lars H., Lörsch, Alisa Martina, Maguire, Nadia, Müller, Sophie, Piso, Pompiliu, Potkrajcic, Vlatko, Reichardt, Peter, Richter, Stephan, Schewe, Simone, Schiffmann, Lars M., Scholten, Felicitas, Striefler, Jana Käthe, Schwarzbach, Matthias, Seidensaal, Katharina, Semrau, Sabine, Szkandera, Joanna, Szuszies, Christoph J., Timmermann, Beate, Tuscherer, Armin, Wiegering, Armin, Winkelmann, Moritz T., Kaul, David, and Jakob, Jens

Published
2025
Full Text
View/download PDF

2. Primary intracranial germ cell tumors in adolescents and adults: Results of an international, multicenter, retrospective cohort study.

Author

Zschaebitz, Stefanie, primary, Heck, Clarissa K, additional, Kasim, Rega, additional, Seidel, Christoph Alexander, additional, Blum, Veronika, additional, Paffenholz, Pia, additional, Hentrich, Marcus, additional, Cathomas, Richard, additional, Augustin, Marinela, additional, Timmer, Marco, additional, Schäfers, Christoph, additional, Schäfer, Sophia, additional, Harrabi, Semi, additional, Jaeger, Dirk, additional, Beyer, Joerg, additional, Lorch, Anja, additional, and Ochsenreither, Sebastian, additional

Published
2024
Full Text
View/download PDF

3. Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13)

Author

Kasper, Bernd, primary, Pink, Daniel, additional, Rothermundt, Christian, additional, Richter, Stephan, additional, Augustin, Marinela, additional, Kollar, Attila, additional, Kunitz, Annegret, additional, Eisterer, Wolfgang, additional, Gaidzik, Verena, additional, Brodowicz, Thomas, additional, Egerer, Gerlinde, additional, Reichardt, Peter, additional, Hohenberger, Peter, additional, and Schuler, Markus K., additional

Published
2024
Full Text
View/download PDF

4. Community-driven development of a modified progression-free survival ratio for precision oncology

Author

Mock, Andreas, Heilig, Christoph E, Kreutzfeldt, Simon, Huebschmann, Daniel, Heining, Christoph, Schröck, Evelin, Brors, Benedikt, Stenzinger, Albrecht, Jäger, Dirk, Schlenk, Richard, Glimm, Hanno, Fröhling, Stefan, Horak, Peter, Apostolidis, Leonidas, Augustin, Marinela, Aust, Daniela, Bhatti, Irfan Ahmed, Bloehdorn, Johannes, Brendel, Cornelia, Britschgi, Christian, Braess, Jan, Burdach, Stefan, Busch, Elena, Casuscelli, Jozefina, Desuki, Alexander, Deutsch, Thomas, Dietrich, Mareike, Ehmer, Ursula, Ettrich, Thomas J, Falkenhorst, Johanna, Fehm, Tanja, Flörcken, Anne, Forschner, Andrea, Fuxius, Stefan, Gonzales-Carmona, Maria, Griesinger, Frank, Grill, Sabine, Gröschel, Stefan, Haag, Georg Martin, Haag, Ulrich, Halama, Niels, Hebart, Holger, Heidger, Nina, Hermes, Barbara, Hess, Georg, Hettmer, Simone, Hoechstetter, Manuela, Hoffmann, Martin, Hüttner, Felix J, Illert, Anna L, Jenzer, Maximilian, Kasper, Bernd, Kasper-Virchow, Stefan, Kindler, Thomas, Koscielniak, Ewa, Krönke, Jan, Kühn, Michael, Kunzmann, Volker, Lang, Alois, Leichsenring, Jonas, Livingstone, Elisabeth, Liotta, Lucia, Luley, Kim, Mack, Elisabeth, Martens, Uwe M, Metzeler, Klaus, Middeke, Jan Moritz, Möhrmann, Lino, Jayarama-Naidu, Roopa, Pape, Ulrich-Frank, Perkhofer, Lukas, Pfeufer, Arne, Pixberg, Constantin, Quante, Michael, Rendenbach, Bernhard, Rieke, Damian, Rothermundt, Christian, Sagerer, Andre Norbert, Salzmann, Martin, Saur, Dieter, Schilling, Bastian, Schleicher, Jan, Schlenska-Lange, Anke, Schmidt, Thomas, Schmitz, Sophia, Schölch, Sebastian, Shah, Rajiv, Shoumariyeh, Khalid, Siebenhüner, Alexander, Singh, Martin, Siveke, Jens, Springfeld, Christoph, Starke, Helen, Strobel, Sophia, Teleanu, Veronica, Thon, Niklas, Wagner, Sebastian, Walle, Thomas, Westphalen, Benedikt, Whitlock, Bettina, Winkler, Eva, Wirsik, Naita Maren, Woydack, Lena, Bois, Angelika Zabel-du, and Zschäbitz, Stefanie

Published
2019
Full Text
View/download PDF

5. ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

Author

Duell, Johannes, primary, Abrisqueta, Pau, additional, Andre, Marc, additional, Augustin, Marinela, additional, Gaidano, Gianluca, additional, Barca, Eva González, additional, Jurczak, Wojciech, additional, Kalakonda, Nagesh, additional, Liberati, Anna Marina, additional, Maddocks, Kami J, additional, Menne, Tobias, additional, Nagy, Zsolt, additional, Tournilhac, Olivier, additional, Bakuli, Abhishek, additional, Amin, Aasim, additional, Gurbanov, Konstantin, additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

6. POSTER: ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

Author

Duell, Johannes, primary, Abrisqueta, Pau, additional, Andre, Marc, additional, Augustin, Marinela, additional, Gaidano, Gianluca, additional, Barca, Eva González, additional, Jurczak, Wojciech, additional, Kalakonda, Nagesh, additional, Liberati, Anna Marina, additional, Maddocks, Kami J, additional, Menne, Tobias, additional, Nagy, Zsolt, additional, Tournilhac, Olivier, additional, Bakuli, Abhishek, additional, Amin, Aasim, additional, Gurbanov, Konstantin, additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

7. P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY

Author

Duell, Johannes, primary, Abrisqueta, Pau, additional, Andre, Marc, additional, Augustin, Marinela, additional, Gaidano, Gianluca, additional, González Barca, Eva, additional, Jurczak, Wojciech, additional, Kalakonda, Nagesh, additional, Marina Liberati, Anna, additional, Maddocks, Kami, additional, Menne, Tobias, additional, Nagy, Zsolt, additional, Tournilhac, Olivier, additional, Bakuli, Abhishek, additional, Amin, Aasim, additional, Gurbanov, Konstantin, additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

8. Treatment options and outcome of patients with metastatic renal cell carcinoma with brain or bone metastases: Real world evidence from a German retrospective multi-center analysis.

Author

Paffenholz, Pia, Ivanyi, Philipp, Casuscelli, Jozefina, Stelmach, Ramona, Guer, Melis, Schlack, Katrin, Darr, Christopher, Rinderknecht, Emily, Hilser, Thomas, Flegar, Luka, Klee, Melanie, Seidl, Daniel, Handke, Analena, Nestler, Tim, Mattigk, Angelika, Augustin, Marinela, Hijazi, Sameh, Rehlinghaus, Marc, Heidenreich, Axel, and Gruenwald, Viktor

Published
2024
Full Text
View/download PDF

9. Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.

Author

Augustin, Marinela, Laguerre, Brigitte, Baldini, Capucine, Zedan, Ahmed H., Gonzalez-Billalabeitia, Enrique, Fong, Peter C.C., Zukov, Ruslan, Hammerer, Peter, Prentice, Mark, Shore, Neal D., Necchi, Andrea, Todenhöfer, Tilman, Kessler, Elizabeth R., Köse, Fatih, Gurney, Howard, Perez Valderrama, Begona, Zhu, Pengfei, Imai, Kentaro, liu, yingjie, and McDermott, Raymond S.

Published
2024
Full Text
View/download PDF

10. Abstract CT022: Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study

Author

Duell, Johannes, primary, Abrisqueta, Pau, additional, Andre, Marc, additional, Augustin, Marinela, additional, Gaidano, Gianluca, additional, Barca, Eva González, additional, Jurczak, Wojciech, additional, Kalakonda, Nagesh, additional, Liberati, Anna Marina, additional, Maddocks, Kami J., additional, Menne, Tobias, additional, Nagy, Zsolt, additional, Tournilhac, Olivier, additional, Bakuli, Abhishek, additional, Amin, Aasim, additional, Gurbanov, Konstantin, additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

11. Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Author

Horak, Peter, primary, Heining, Christoph, primary, Kreutzfeldt, Simon, primary, Hutter, Barbara, primary, Mock, Andreas, primary, Hüllein, Jennifer, primary, Fröhlich, Martina, primary, Uhrig, Sebastian, primary, Jahn, Arne, primary, Rump, Andreas, primary, Gieldon, Laura, primary, Möhrmann, Lino, primary, Hanf, Dorothea, primary, Teleanu, Veronica, primary, Heilig, Christoph E., primary, Lipka, Daniel B., primary, Allgäuer, Michael, primary, Ruhnke, Leo, primary, Laßmann, Andreas, primary, Endris, Volker, primary, Neumann, Olaf, primary, Penzel, Roland, primary, Beck, Katja, primary, Richter, Daniela, primary, Winter, Ulrike, primary, Wolf, Stephan, primary, Pfütze, Katrin, primary, Geörg, Christina, primary, Meißburger, Bettina, primary, Buchhalter, Ivo, primary, Augustin, Marinela, primary, Aulitzky, Walter E., primary, Hohenberger, Peter, primary, Kroiss, Matthias, primary, Schirmacher, Peter, primary, Schlenk, Richard F., primary, Keilholz, Ulrich, primary, Klauschen, Frederick, primary, Folprecht, Gunnar, primary, Bauer, Sebastian, primary, Siveke, Jens Thomas, primary, Brandts, Christian H., primary, Kindler, Thomas, primary, Boerries, Melanie, primary, Illert, Anna L., primary, von Bubnoff, Nikolas, primary, Jost, Philipp J., primary, Spiekermann, Karsten, primary, Bitzer, Michael, primary, Schulze-Osthoff, Klaus, primary, von Kalle, Christof, primary, Klink, Barbara, primary, Brors, Benedikt, primary, Stenzinger, Albrecht, primary, Schröck, Evelin, primary, Hübschmann, Daniel, primary, Weichert, Wilko, primary, Glimm, Hanno, primary, and Fröhling, Stefan, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Tables S1-S7 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Author

Horak, Peter, primary, Heining, Christoph, primary, Kreutzfeldt, Simon, primary, Hutter, Barbara, primary, Mock, Andreas, primary, Hüllein, Jennifer, primary, Fröhlich, Martina, primary, Uhrig, Sebastian, primary, Jahn, Arne, primary, Rump, Andreas, primary, Gieldon, Laura, primary, Möhrmann, Lino, primary, Hanf, Dorothea, primary, Teleanu, Veronica, primary, Heilig, Christoph E., primary, Lipka, Daniel B., primary, Allgäuer, Michael, primary, Ruhnke, Leo, primary, Laßmann, Andreas, primary, Endris, Volker, primary, Neumann, Olaf, primary, Penzel, Roland, primary, Beck, Katja, primary, Richter, Daniela, primary, Winter, Ulrike, primary, Wolf, Stephan, primary, Pfütze, Katrin, primary, Geörg, Christina, primary, Meißburger, Bettina, primary, Buchhalter, Ivo, primary, Augustin, Marinela, primary, Aulitzky, Walter E., primary, Hohenberger, Peter, primary, Kroiss, Matthias, primary, Schirmacher, Peter, primary, Schlenk, Richard F., primary, Keilholz, Ulrich, primary, Klauschen, Frederick, primary, Folprecht, Gunnar, primary, Bauer, Sebastian, primary, Siveke, Jens Thomas, primary, Brandts, Christian H., primary, Kindler, Thomas, primary, Boerries, Melanie, primary, Illert, Anna L., primary, von Bubnoff, Nikolas, primary, Jost, Philipp J., primary, Spiekermann, Karsten, primary, Bitzer, Michael, primary, Schulze-Osthoff, Klaus, primary, von Kalle, Christof, primary, Klink, Barbara, primary, Brors, Benedikt, primary, Stenzinger, Albrecht, primary, Schröck, Evelin, primary, Hübschmann, Daniel, primary, Weichert, Wilko, primary, Glimm, Hanno, primary, and Fröhling, Stefan, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figures S1-S10 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Author

Horak, Peter, primary, Heining, Christoph, primary, Kreutzfeldt, Simon, primary, Hutter, Barbara, primary, Mock, Andreas, primary, Hüllein, Jennifer, primary, Fröhlich, Martina, primary, Uhrig, Sebastian, primary, Jahn, Arne, primary, Rump, Andreas, primary, Gieldon, Laura, primary, Möhrmann, Lino, primary, Hanf, Dorothea, primary, Teleanu, Veronica, primary, Heilig, Christoph E., primary, Lipka, Daniel B., primary, Allgäuer, Michael, primary, Ruhnke, Leo, primary, Laßmann, Andreas, primary, Endris, Volker, primary, Neumann, Olaf, primary, Penzel, Roland, primary, Beck, Katja, primary, Richter, Daniela, primary, Winter, Ulrike, primary, Wolf, Stephan, primary, Pfütze, Katrin, primary, Geörg, Christina, primary, Meißburger, Bettina, primary, Buchhalter, Ivo, primary, Augustin, Marinela, primary, Aulitzky, Walter E., primary, Hohenberger, Peter, primary, Kroiss, Matthias, primary, Schirmacher, Peter, primary, Schlenk, Richard F., primary, Keilholz, Ulrich, primary, Klauschen, Frederick, primary, Folprecht, Gunnar, primary, Bauer, Sebastian, primary, Siveke, Jens Thomas, primary, Brandts, Christian H., primary, Kindler, Thomas, primary, Boerries, Melanie, primary, Illert, Anna L., primary, von Bubnoff, Nikolas, primary, Jost, Philipp J., primary, Spiekermann, Karsten, primary, Bitzer, Michael, primary, Schulze-Osthoff, Klaus, primary, von Kalle, Christof, primary, Klink, Barbara, primary, Brors, Benedikt, primary, Stenzinger, Albrecht, primary, Schröck, Evelin, primary, Hübschmann, Daniel, primary, Weichert, Wilko, primary, Glimm, Hanno, primary, and Fröhling, Stefan, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Methods from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Author

Horak, Peter, primary, Heining, Christoph, primary, Kreutzfeldt, Simon, primary, Hutter, Barbara, primary, Mock, Andreas, primary, Hüllein, Jennifer, primary, Fröhlich, Martina, primary, Uhrig, Sebastian, primary, Jahn, Arne, primary, Rump, Andreas, primary, Gieldon, Laura, primary, Möhrmann, Lino, primary, Hanf, Dorothea, primary, Teleanu, Veronica, primary, Heilig, Christoph E., primary, Lipka, Daniel B., primary, Allgäuer, Michael, primary, Ruhnke, Leo, primary, Laßmann, Andreas, primary, Endris, Volker, primary, Neumann, Olaf, primary, Penzel, Roland, primary, Beck, Katja, primary, Richter, Daniela, primary, Winter, Ulrike, primary, Wolf, Stephan, primary, Pfütze, Katrin, primary, Geörg, Christina, primary, Meißburger, Bettina, primary, Buchhalter, Ivo, primary, Augustin, Marinela, primary, Aulitzky, Walter E., primary, Hohenberger, Peter, primary, Kroiss, Matthias, primary, Schirmacher, Peter, primary, Schlenk, Richard F., primary, Keilholz, Ulrich, primary, Klauschen, Frederick, primary, Folprecht, Gunnar, primary, Bauer, Sebastian, primary, Siveke, Jens Thomas, primary, Brandts, Christian H., primary, Kindler, Thomas, primary, Boerries, Melanie, primary, Illert, Anna L., primary, von Bubnoff, Nikolas, primary, Jost, Philipp J., primary, Spiekermann, Karsten, primary, Bitzer, Michael, primary, Schulze-Osthoff, Klaus, primary, von Kalle, Christof, primary, Klink, Barbara, primary, Brors, Benedikt, primary, Stenzinger, Albrecht, primary, Schröck, Evelin, primary, Hübschmann, Daniel, primary, Weichert, Wilko, primary, Glimm, Hanno, primary, and Fröhling, Stefan, primary

Published
2023
Full Text
View/download PDF

15. Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26]

Author

Yu, Evan Y., primary, Piulats, Josep M., additional, Gravis, Gwenaelle, additional, Fong, Peter C.C., additional, Todenhöfer, Tilman, additional, Laguerre, Brigitte, additional, Arranz, Jose A., additional, Oudard, Stephane, additional, Massard, Christophe, additional, Heinzelbecker, Julia, additional, Nordquist, Luke T., additional, Carles, Joan, additional, Kolinsky, Michael P., additional, Augustin, Marinela, additional, Gurney, Howard, additional, Tafreshi, Ali, additional, Li, Xin Tong, additional, Qiu, Ping, additional, Poehlein, Christian H., additional, Schloss, Charles, additional, and de Bono, Johann S., additional

Published
2023
Full Text
View/download PDF

17. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

Author

Yu, Evan Y., primary, Piulats, Josep M., additional, Gravis, Gwenaelle, additional, Fong, Peter C.C., additional, Todenhöfer, Tilman, additional, Laguerre, Brigitte, additional, Arranz, Jose A., additional, Oudard, Stephane, additional, Massard, Christophe, additional, Heinzelbecker, Julia, additional, Nordquist, Luke T., additional, Carles, Joan, additional, Kolinsky, Michael P., additional, Augustin, Marinela, additional, Gurney, Howard, additional, Tafreshi, Ali, additional, Li, Xin Tong, additional, Qiu, Ping, additional, Poehlein, Christian H., additional, Schloss, Charles, additional, and de Bono, Johann S., additional

Published
2023
Full Text
View/download PDF

18. Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial

Author

Grünwald, Viktor, primary, Pink, Daniel, additional, Egerer, Gerlinde, additional, Schalk, Enrico, additional, Augustin, Marinela, additional, Deinzer, Christoph K. W., additional, Kob, Viola, additional, Reichert, Dietmar, additional, Kebenko, Maxim, additional, Brandl, Stephan, additional, Hahn, Dennis, additional, Lindner, Lars H., additional, Hoiczyk, Mathias, additional, Ringsdorf, Uta, additional, Hanker, Lars C., additional, Hempel, Dirk, additional, De Rivas, Beatriz, additional, Wismann, Tobias, additional, and Ivanyi, Philipp, additional

Published
2022
Full Text
View/download PDF

20. MP24-14 PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS

Author

Nordquist, Luke T., primary, Yu, Evan Y., additional, Piulats, Josep M., additional, Gravis, Gwenaelle, additional, Fong, Peter C.C., additional, Todenhoefer, Tilman, additional, Laguerre, Brigitte, additional, Arranz Arija, Jose Angel, additional, Oudard, Stephane, additional, Massard, Christophe, additional, Stoeckle, Michael, additional, Carles, Joan, additional, Kolinsky, Michael Paul, additional, Augustin, Marinela, additional, Gurney, Howard, additional, Tafreshi, Ali, additional, Li, Xin Tong, additional, Poehlein, Christian Heinrich, additional, Schloss, Charles, additional, and de Bono, Johann S., additional

Published
2021
Full Text
View/download PDF

21. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Author

Duell, Johannes, primary, Maddocks, Kami J., additional, González-Barca, Eva, additional, Jurczak, Wojciech, additional, Liberati, Anna Marina, additional, De Vos, Sven, additional, Nagy, Zsolt, additional, Obr, Aleš, additional, Gaidano, Gianluca, additional, Abrisqueta, Pau, additional, Kalakonda, Nagesh, additional, André, Marc, additional, Dreyling, Martin, additional, Menne, Tobias, additional, Tournilhac, Olivier, additional, Augustin, Marinela, additional, Rosenwald, Andreas, additional, Dirnberger-Hertweck, Maren, additional, Weirather, Johannes, additional, Ambarkhane, Sumeet, additional, and Salles, Gilles, additional

Published
2021
Full Text
View/download PDF

22. Preinfection laboratory parameters may predict COVID‐19 severity in tumor patients

Author

Kiani, Alexander, primary, Roesch, Romina, additional, Wendtner, Clemens M., additional, Kullmann, Frank, additional, Kubin, Thomas, additional, Südhoff, Thomas, additional, Augustin, Marinela, additional, Schaich, Markus, additional, Müller‐Naendrup, Clemens, additional, Illerhaus, Gerald, additional, Hartmann, Frank, additional, Hebart, Holger, additional, Seggewiss‐Bernhardt, Ruth, additional, Bentz, Martin, additional, Späth‐Schwalbe, Ernst, additional, Reimer, Peter, additional, Kaiser, Ulrich, additional, Kapp, Markus, additional, Graeven, Ullrich, additional, Chemnitz, Jens‐Marcus, additional, Baesecke, Jörg, additional, Lambertz, Helmut, additional, and Naumann, Ralph, additional

Published
2021
Full Text
View/download PDF

23. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Author

Horak, Peter, primary, Heining, Christoph, additional, Kreutzfeldt, Simon, additional, Hutter, Barbara, additional, Mock, Andreas, additional, Hüllein, Jennifer, additional, Fröhlich, Martina, additional, Uhrig, Sebastian, additional, Jahn, Arne, additional, Rump, Andreas, additional, Gieldon, Laura, additional, Möhrmann, Lino, additional, Hanf, Dorothea, additional, Teleanu, Veronica, additional, Heilig, Christoph E., additional, Lipka, Daniel B., additional, Allgäuer, Michael, additional, Ruhnke, Leo, additional, Laßmann, Andreas, additional, Endris, Volker, additional, Neumann, Olaf, additional, Penzel, Roland, additional, Beck, Katja, additional, Richter, Daniela, additional, Winter, Ulrike, additional, Wolf, Stephan, additional, Pfütze, Katrin, additional, Geörg, Christina, additional, Meißburger, Bettina, additional, Buchhalter, Ivo, additional, Augustin, Marinela, additional, Aulitzky, Walter E., additional, Hohenberger, Peter, additional, Kroiss, Matthias, additional, Schirmacher, Peter, additional, Schlenk, Richard F., additional, Keilholz, Ulrich, additional, Klauschen, Frederick, additional, Folprecht, Gunnar, additional, Bauer, Sebastian, additional, Siveke, Jens Thomas, additional, Brandts, Christian H., additional, Kindler, Thomas, additional, Boerries, Melanie, additional, Illert, Anna L., additional, von Bubnoff, Nikolas, additional, Jost, Philipp J., additional, Spiekermann, Karsten, additional, Bitzer, Michael, additional, Schulze-Osthoff, Klaus, additional, von Kalle, Christof, additional, Klink, Barbara, additional, Brors, Benedikt, additional, Stenzinger, Albrecht, additional, Schröck, Evelin, additional, Hübschmann, Daniel, additional, Weichert, Wilko, additional, Glimm, Hanno, additional, and Fröhling, Stefan, additional

Published
2021
Full Text
View/download PDF

24. Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Author

Koschmieder, Steffen, Isfort, Susanne, Teichmann, Lino L., Schafhausen, Philippe, Heidel, Florian, Hochhaus, Andreas, Griesshammer, Martin, Sockel, Katja, Jost, Philipp, Wolleschak, Denise, Döhner, Konstanze, Goethert, Joachim R., Radsak, Markus P., Augustin, Marinela, Becker, Heiko, Giagounidis, Aristoteles, Schaich, Markus, Klausmann, Martine, Von Bubnoff, Nikolas, Stegelmann, Frank, Kortmann, Maike, Frank, Julia, Hellmich, Martin, and Brümmendorf, Tim H.

Published
2023
Full Text
View/download PDF

25. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Duell, Johannes, Maddocks, Kami J., González-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, De Vos, Sven, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, Abrisqueta, Pau, Kalakonda, Nagesh, André, Marc, Dreyling, Martin, Menne, Tobias, Tournilhac, Olivier, Augustin, Marinela, Rosenwald, Andreas, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet, Salles, Gilles, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Duell, Johannes, Maddocks, Kami J., González-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, De Vos, Sven, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, Abrisqueta, Pau, Kalakonda, Nagesh, André, Marc, Dreyling, Martin, Menne, Tobias, Tournilhac, Olivier, Augustin, Marinela, Rosenwald, Andreas, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet, and Salles, Gilles

Abstract

Not available.

Published
2021

26. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Duell, Johannes, Maddocks, Kami J, González-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, De Vos, Sven, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, Abrisqueta, Pau, Kalakonda, Nagesh, André, Marc, Dreyling, Martin, Menne, Tobias, Tournilhac, Olivier, Augustin, Marinela, Rosenwald, Andreas, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet, Salles, Gilles, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Duell, Johannes, Maddocks, Kami J, González-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, De Vos, Sven, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, Abrisqueta, Pau, Kalakonda, Nagesh, André, Marc, Dreyling, Martin, Menne, Tobias, Tournilhac, Olivier, Augustin, Marinela, Rosenwald, Andreas, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet, and Salles, Gilles

Abstract

Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability profile in the open-label, single-arm, phase II L-MIND study (NCT02399085) of autologous stem-cell transplant (ASCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). To assess long-term outcomes, we report an updated analysis with ≥35 months' follow-up. Patients were aged >18 years, had 1-3 prior systemic therapies (including ≥1 CD20-targeting regimen) and Eastern Cooperative Oncology Group performance status 0-2. Patients received 28-day cycles of tafasitamab (12 mg/kg intravenously), once weekly during cycles 1-3, then every 2 weeks during cycles 4-12. Lenalidomide (25 mg orally) was administered on days 1-21 of cycles 1-12. After cycle 12, progression-free patients received tafasitamab every 2 weeks until disease progression (PD). The primary endpoint was best objective response rate (ORR). After ≥35 months' follow-up (data cut-off: October 30, 2020), ORR was 57.5% (n=46/80), including a complete response in 40.0% of patients (n=32/80) and a partial response in 17.5% of patients (n=14/80). Median duration of response (DoR) was 43.9 months (95% CI: 26.1-not reached [NR]); median overall survival (OS) was 33.5 months (18.3-NR); and median progression-free survival was 11.6 months (6.3-45.7). There were no unexpected toxicities. Subgroup analyses revealed consistent long-term efficacy results across most patient subgroups. This extended L-MIND follow-up confirms the long DoR, meaningful OS, and welldefined safety profile of tafasitamab plus lenalidomide followed by tafasitamab monotherapy in ASCT-ineligible patients with R/R DLBCL.

Published
2021

27. Thrombospondin-2 and LDH are putative predictive biomarkers for treatment with everolimus in second-line metastatic clear Ccll renal cell carcinoma (MARC-2 study)

Author

Zeuschner, Philip Alexander, Hölters, Sebastian, Stöckle, Michael, Seliger, Barbara, Müller, Anja, Bachmann, Hagen Sjard, Grünwald, Viktor, Christoph, Daniel C., Stenzl, Arnulf, Grimm, Marc-Oliver, Brüning, Fabian, Goebell, Peter Jürgen, Augustin, Marinela, Roos, Frederik, Harde, Johanna, Benz-Rüd, Iris, Staehler, Michael, Junker, Kerstin, Zeuschner, Philip Alexander, Hölters, Sebastian, Stöckle, Michael, Seliger, Barbara, Müller, Anja, Bachmann, Hagen Sjard, Grünwald, Viktor, Christoph, Daniel C., Stenzl, Arnulf, Grimm, Marc-Oliver, Brüning, Fabian, Goebell, Peter Jürgen, Augustin, Marinela, Roos, Frederik, Harde, Johanna, Benz-Rüd, Iris, Staehler, Michael, and Junker, Kerstin

Abstract

Simple Summary: Treatment of metastatic renal cell carcinoma (mRCC) remains a challenge due to the lack of biomarkers indicating the optimal drug for each patient. This study analyzed blood samples of patients with predominant clear cell mRCC who were treated with the mTOR inhibitor everolimus after failure of one prior tumor therapy. In an exploratory approach, predictive blood biomarkers were searched. We found lower levels of the protein thrombospondin-2 (TSP-2) at the start of the therapy and higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation to be associated with therapy response. Of note, these blood biomarkers had a higher predictive value than baseline patient parameters or risk classifications. Polymorphisms in the mTOR gene appeared to be associated with therapy response, but were not significant. To conclude, it seems feasible to identify patients showing longtime responses to everolimus and possible to increase tumor therapy response rates based on biomarkers for individual therapy selection. Abstract: There is an unmet need for predictive biomarkers in metastatic renal cell carcinoma (mRCC) therapy. The phase IV MARC-2 trial searched for predictive blood biomarkers in patients with predominant clear cell mRCC who benefit from second-line treatment with everolimus. In an exploratory approach, potential biomarkers were assessed employing proteomics, ELISA, and polymorphism analyses. Lower levels of angiogenesis-related protein thrombospondin-2 (TSP-2) at baseline (≤665 parts per billion, ppb) identified therapy responders with longer median progression-free survival (PFS; ≤665 ppb at baseline: 6.9 months vs. 1.8, p = 0.005). Responders had higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation (>27.14 nmol/L), associated with a longer median PFS (3.8 months vs. 2.2, p = 0.013) and improved overall survival (OS; 31.0 months vs. 14.0 months, p < 0.001). Baseline TSP-2 levels had a stronger re

Published
2021

28. Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)

Author

Zeuschner, Philip, primary, Hölters, Sebastian, additional, Stöckle, Michael, additional, Seliger, Barbara, additional, Mueller, Anja, additional, Bachmann, Hagen S., additional, Grünwald, Viktor, additional, Christoph, Daniel C., additional, Stenzl, Arnulf, additional, Grimm, Marc-Oliver, additional, Brüning, Fabian, additional, Goebell, Peter J., additional, Augustin, Marinela, additional, Roos, Frederik, additional, Harde, Johanna, additional, Benz-Rüd, Iris, additional, Staehler, Michael, additional, and Junker, Kerstin, additional

Published
2021
Full Text
View/download PDF

29. Prognostic value of pre-infection routine laboratory parameters for COVID-19 mortality in tumor patients: Results of the ADHOK Coronavirus Tumor Registry.

Author

Roesch, Romina, primary, Suedhoff, Thomas, additional, Wendtner, Clemens M., additional, Kullmann, Frank, additional, Kubin, Thomas, additional, Schaich, Markus, additional, Mueller-Naendrup, Clemens U., additional, Augustin, Marinela, additional, Hartmann, Frank, additional, Illerhaus, Gerald, additional, Hebart, Holger Frithjof, additional, Seggewiss-Bernhardt, Ruth, additional, Graeven, Ullrich, additional, Naumann, Ralph, additional, and Kiani, Alexander, additional

Published
2021
Full Text
View/download PDF

30. Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

Author

González-Barca, Eva, primary, Duell, Johannes, additional, Cavallo, Federica, additional, Sancho, Juan-Manuel, additional, Nagy, Zsolt, additional, Abrisqueta, Pau, additional, Panizo, Carlos, additional, Augustin, Marinela, additional, Weirather, Johannes, additional, Ambarkhane, Sumeet, additional, Maddocks, Kami J., additional, Kalakonda, Nagesh, additional, and Salles, Gilles, additional

Published
2020
Full Text
View/download PDF

31. Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial

Author

Staehler, Michael, primary, Stöckle, Michael, additional, Christoph, Daniel C., additional, Stenzl, Arnulf, additional, Potthoff, Karin, additional, Grimm, Marc‐Oliver, additional, Klein, Dunja, additional, Harde, Johanna, additional, Brüning, Fabian, additional, Goebell, Peter J., additional, Augustin, Marinela, additional, Roos, Frederik, additional, Benz‐Rüd, Iris, additional, Marschner, Norbert, additional, and Grünwald, Viktor, additional

Published
2020
Full Text
View/download PDF

32. ABCL-170: Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Salles, Gilles, primary, Duell, Johannes, additional, González-Barca, Eva, additional, Jurczak, Wojciech, additional, Marina Liberati, Anna, additional, de Vos, Sven, additional, Nagy, Zsolt, additional, Obr, Aleš, additional, Gaidano, Gianluca, additional, Abrisqueta, Pau, additional, Kalakonda, Nagesh, additional, André, Marc, additional, Dreyling, Martin, additional, Menne, Tobias, additional, Tournilhac, Olivier, additional, Augustin, Marinela, additional, Dirnberger-Hertweck, Maren, additional, Weirather, Johannes, additional, Ambarkhane, Sumeet, additional, and Maddocks, Kami J, additional

Published
2020
Full Text
View/download PDF

33. Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.

Author

Yu, Evan Y., primary, Piulats Rodriguez, Jose Maria M., additional, Gravis, Gwenaelle, additional, Laguerre, Brigitte, additional, Arranz Arija, Jose Angel, additional, Oudard, Stephane, additional, Fong, Peter C.C., additional, Kolinsky, Michael Paul, additional, Augustin, Marinela, additional, Todenhöfer, Tilman, additional, Kam, Audrey E., additional, Gurney, Howard, additional, Tafreshi, Ali, additional, Retz, Margitta, additional, Berry, William R., additional, Mar, Nataliya, additional, Wu, Haiyan, additional, Qiu, Ping, additional, Schloss, Charles, additional, and De Bono, Johann S., additional

Published
2020
Full Text
View/download PDF

34. Radiochemotherapy with gemcitabine as radiosensitizer in patients with soft tissue sarcoma.

Author

Augustin, Marinela, primary, Wilhelm, Martin, additional, Reichert, Bert, additional, Siegler, Gabriele Margareta, additional, Dreier, Juergen, additional, Rottmann, Michael, additional, Blos, Martin, additional, Kalisch, Alexander, additional, Dressler, Sabine, additional, Stein, Hubert, additional, Koehler, Jens, additional, Papadopoulos, Thomas, additional, Meyer, Christian, additional, Hohenberger, Peter, additional, Jakob, Jens, additional, Vassos, Nikolaos, additional, Grehn, Christian, additional, and Albrecht, Clemens, additional

Published
2020
Full Text
View/download PDF

35. A Randomized Phase II Study of Durvalumab and Tremelimumab Compared to Doxorubicin in Patients with Advanced or Metastatic Soft Tissue Sarcoma (Medisarc, AIO-STS-0415)

Author

Gruenwald, Viktor, Ivanyi, Philipp, Hermes, Barbara, Tuchscherer, Armin, Pink, Daniel, Bauer, Sebastian, Lindner, Lars, Augustin, Marinela, Blocks, Andreas, Richter, Stephan, Reichardt, Peter, Crysandt, Martina, Hipper, Annette, Fischer, Marc, Gruenwald, Viktor, Ivanyi, Philipp, Hermes, Barbara, Tuchscherer, Armin, Pink, Daniel, Bauer, Sebastian, Lindner, Lars, Augustin, Marinela, Blocks, Andreas, Richter, Stephan, Reichardt, Peter, Crysandt, Martina, Hipper, Annette, and Fischer, Marc

Published
2020

36. CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study.

Author

Duell, Johannes, Obr, Aleš, Augustin, Marinela, Endell, Jan, Liu, Hao, Geiger, Sabine, Silverman, Ian M., Ambarkhane, Sumeet, and Rosenwald, Andreas

Subjects
CD19 antigen, DIFFUSE large B-cell lymphomas, LENALIDOMIDE, MANTLE cell lymphoma, ANTIBODY-dependent cell cytotoxicity
Abstract

This contrasts with reports of CD19 expression loss after bispecific anti-CD19 treatment and CD19-directed CAR T-cell treatments [[7]]. CD19 is an important target for novel anti-lymphoma treatments as it is broadly and homogenously expressed across many B-cell malignancies [[1]]. DNA and RNA analyses did not find evidence for CD19 mutations, dominant exon skipping or loss of CD19 mRNA expression, which would be indicative of resistance to further CD19-targeted therapy. [Extracted from the article]

Published
2022
Full Text
View/download PDF

37. KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Author

Yu, Evan Y., primary, Piulats, Josep M., additional, Gravis, Gwenaelle, additional, Laguerre, Brigitte, additional, Arranz Arija, Jose Angel, additional, Oudard, Stephane, additional, Fong, Peter C.C., additional, Kolinsky, Michael Paul, additional, Augustin, Marinela, additional, Feyerabend, Susan, additional, Kam, Audrey E., additional, Gurney, Howard, additional, Tafreshi, Ali, additional, Retz, Margitta, additional, Berry, William R., additional, Mar, Nataliya, additional, Wu, Helen, additional, Schloss, Charles, additional, Poehlein, Christian Heinrich, additional, and De Bono, Johann S., additional

Published
2020
Full Text
View/download PDF

38. Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.

Author

Yu, Evan Y., primary, Massard, Christophe, additional, Retz, Margitta, additional, Tafreshi, Ali, additional, Carles, Joan, additional, Hammerer, Peter, additional, Fong, Peter C.C., additional, Shore, Neal D., additional, Joshua, Anthony M., additional, Linch, Mark David, additional, Gurney, Howard, additional, Romano, Emanuela, additional, Augustin, Marinela, additional, Piulats, Josep M., additional, Wu, Helen, additional, Schloss, Charles, additional, Poehlein, Christian Heinrich, additional, and De Bono, Johann S., additional

Published
2019
Full Text
View/download PDF

39. Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.

Author

Massard, Christophe, primary, Retz, Margitta, additional, Hammerer, Peter, additional, Quevedo, Fernando, additional, Fong, Peter C.C., additional, Berry, William R., additional, Gurney, Howard, additional, Piulats, Josep M., additional, Joshua, Anthony M., additional, Linch, Mark David, additional, Kolinsky, Michael Paul, additional, Romano, Emanuela, additional, Sridhar, Srikala S., additional, Conter, Henry Jacob, additional, Augustin, Marinela, additional, Wu, Helen, additional, Schloss, Charles, additional, Poehlein, Christian Heinrich, additional, and Yu, Evan Y., additional

Published
2019
Full Text
View/download PDF

40. Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

Author

Yu, Evan Y., primary, Massard, Christophe, additional, Retz, Margitta, additional, Tafreshi, Ali, additional, Carles Galceran, Joan, additional, Hammerer, Peter, additional, Fong, Peter C.C., additional, Shore, Neal D., additional, Joshua, Anthony, additional, Linch, Mark David, additional, Gurney, Howard, additional, Romano, Emanuela, additional, Augustin, Marinela, additional, Piulats, Josep M., additional, Wu, Haiyan, additional, Schloss, Charles, additional, Poehlein, Christian Heinrich, additional, and De Bono, Johann S., additional

Published
2019
Full Text
View/download PDF

41. Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).

Author

Massard, Christophe, primary, Retz, Margitta, additional, Hammerer, Peter, additional, Quevedo, Fernando, additional, Fong, Peter C.C., additional, Berry, William R., additional, Gurney, Howard, additional, Piulats, Josep M., additional, Joshua, Anthony, additional, Linch, Mark David, additional, Kolinsky, Michael, additional, Romano, Emanuela, additional, Sridhar, Srikala S., additional, Conter, Henry Jacob, additional, Augustin, Marinela, additional, Wu, Haiyan, additional, Schloss, Charles, additional, Poehlein, Christian Heinrich, additional, and Yu, Evan Y., additional

Published
2019
Full Text
View/download PDF

42. Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial.

Author

Staehler, Michael, Stöckle, Michael, Christoph, Daniel C., Stenzl, Arnulf, Potthoff, Karin, Grimm, Marc‐Oliver, Klein, Dunja, Harde, Johanna, Brüning, Fabian, Goebell, Peter J., Augustin, Marinela, Roos, Frederik, Benz‐Rüd, Iris, Marschner, Norbert, and Grünwald, Viktor

Subjects
VASCULAR endothelial growth factor receptors, RENAL cell carcinoma, GASTROINTESTINAL hemorrhage, PROPORTIONAL hazards models, EVEROLIMUS
Abstract

MARC‐2, a prospective, multicenter phase IV trial, aimed to investigate clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of one initial vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) therapy and to identify subgroups benefiting most, based on clinical characteristics and biomarkers. Patients with clear cell mRCC failing one initial VEGFR‐TKI received everolimus until progression or unacceptable toxicity. Primary endpoint was 6‐month progression‐free survival rate (6moPFS). Secondary endpoints were overall response rate (ORR), PFS, overall survival (OS), and safety. Between 2011 and 2015, 63 patients were enrolled. Median age was 65.4 years (range 43.3‐81.1). 6moPFS was 39.3% (95% confidence interval [CI], 27.0‐51.3) overall, 54.4% (95% CI, 35.2‐70.1) vs 23.7% (95% CI, 10.5‐39.9) for patients aged ≥65 vs <65 years and 51.4% (95% CI, 34.7‐65.7) vs 18.2% (95% CI, 5.7‐36.3) for patients with body mass index (BMI) >25 vs ≤25 kg/m2. A Cox proportional hazards model confirmed a longer PFS for patients aged ≥65 years (hazard ratio [HR] 0.46; 95% CI, 0.26‐0.80) and a longer OS for patients with BMI >25 kg/m2 (HR 0.36; 95% CI, 0.18‐0.71). Median PFS and median OS were 3.8 months (95% CI, 3.2‐6.2) and 16.8 months (95% CI, 14.3‐24.3). ORR was 7.9% and disease control rate was 60.3%. No new safety signals emerged. Most common adverse events were stomatitis (31.7%), fatigue (31.7%), and anemia (30.2%). One patient died from treatment‐related upper gastrointestinal hemorrhage. Everolimus remains a safe and effective treatment option for mRCC patients after one prior VEGFR‐TKI therapy. Patients aged ≥65 years and patients with BMI >25 kg/m2 benefited most. What's new? While different novel treatment options have been approved for the vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) refractory setting in metastatic renal cell carcinoma (mRCC), choosing the optimal second‐line therapy regimen remains a biologic and therapeutic challenge. The MARC‐2 phase IV trial aimed to investigate clinical outcomes in mRCC patients treated with everolimus after failure of one VEGFR‐TKI therapy and to identify subgroups benefiting most. According to the data, everolimus remains a safe and effective treatment option for mRCC patients after one prior VEGFR‐TKI therapy, with the greatest benefit seen in patients ≥65 years or with BMI >25 kg/m2. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results